Supporting Access to Essential Medicines in Developing and Conflict-Affected Regions
Ken AertsIn many developing regions and conflict-affected areas, access to essential medicines and healthcare products remains limited. Healthcare systems in these environments are often under pressure, making it more difficult to ensure consistent availability of safe and reliable pharmaceutical products.
Orelia Pharma works with international partners to strengthen the availability of quality-assured medicines in such settings. By focusing on responsible sourcing and distribution, we aim to contribute to continuity of care in environments where access cannot be taken for granted.
In addition to these ongoing efforts, Orelia Pharma closely monitors humanitarian developments where access to medicines is critically impacted. The ongoing situation in Ukraine highlights the importance of resilient and responsive pharmaceutical supply chains in times of crisis.
Strengthening access to medicines in crisis situations requires a balance between speed, reliability and regulatory compliance, supported by trusted partnerships and sustainable distribution practices.
This video provides additional context on the pressure faced by healthcare systems in Ukraine and highlights the importance of reliable access to essential medicines during times of crisis.
Where feasible and in alignment with regulatory and operational frameworks, Orelia Pharma aims to support initiatives that contribute to the continuity of access to essential medicines in affected regions. This includes exploring partnerships, facilitating responsible distribution and supporting healthcare stakeholders operating under challenging conditions.
By prioritising quality, compliance and sustainability, Orelia Pharma seeks to play a constructive role in strengthening access to essential healthcare, particularly in regions facing instability, conflict or resource limitations.